Comparative in vitro activity of A-56268

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Macrolide antibiotics are crucial for treating bacterial infections.
• Emerging resistance necessitates the evaluation of new antimicrobial agents.
• Understanding the in vitro activity spectrum of novel macrolides is essential.

Purpose of the Study:

• To compare the in vitro antimicrobial activity of A-56268 against a wide range of clinical bacterial isolates.
• To evaluate A-56268's efficacy relative to established macrolides like erythromycin, josamycin, and roxithromycin.
• To assess A-56268's activity against erythromycin-resistant bacterial strains.

Main Methods:

• In vitro susceptibility testing of 1,006 clinical bacterial isolates.
• Inclusion of diverse bacterial species: streptococci, enterococci, staphylococci, Neisseria gonorrhoeae, Haemophilus influenzae, and anaerobes.
• Comparative analysis of minimum inhibitory concentrations (MICs) for A-56268, erythromycin, josamycin, and roxithromycin.

Main Results:

• A-56268 exhibited activity comparable to erythromycin against erythromycin-sensitive aerobic and facultatively anaerobic Gram-positive cocci.
• A-56268 demonstrated superior activity against Clostridium spp. and Neisseria gonorrhoeae compared to other tested macrolides.
• Josamycin showed greater activity against anaerobic Gram-positive cocci and the Bacteroides fragilis group.
• Staphylococci resistant to erythromycin remained susceptible to josamycin, but not to A-56268 or roxithromycin.

Conclusions:

• A-56268 is a promising macrolide with broad in vitro activity, particularly against Gram-positive cocci and Neisseria gonorrhoeae.
• Its efficacy is comparable to erythromycin, offering a potential alternative for certain infections.
• Josamycin exhibits unique activity against specific anaerobic bacteria and erythromycin-resistant staphylococci.